Trial reportThe journals of gerontology. Series A, Biological sciences and medical sciences2013
Risk factors associated with cardiovascular events during testosterone administration in older men with mobility limitation.
Trial report in The journals of gerontology. Series A, Biological sciences and medical sciences, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 2 syntheses or guidelines pooled it, 57 citations in OpenAlex.
- Testosterone replacement in men with sexual dysfunction.The Cochrane database of systematic reviews · 2024Pooled it
- Testosterone therapy and cardiovascular events among men: a systematic review and meta-analysis of placebo-controlled randomized trials.BMC medicine · 2013Pooled it
- Metabolic Effects of Testosterone Added to Intensive Lifestyle Intervention in Older Men With Obesity and Hypogonadism.The Journal of clinical endocrinology and metabolism · 2025Trial
- Reduction of calprotectin and phosphate during testosterone therapy in aging men: a randomized controlled trial.Journal of endocrinological investigation · 2017Trial
- Testosterone vs. aromatase inhibitor in older men with low testosterone: effects on cardiometabolic parameters.Andrology · 2017Trial
- Testosterone treatment of men with mild cognitive impairment and low testosterone levels.American journal of Alzheimer's disease and other dementias · 2015Trial
- Trial
- Effects of transdermal testosterone treatment on inflammatory markers in elderly males.Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · 2014Trial
- Musculoskeletal and prostate effects of combined testosterone and finasteride administration in older hypogonadal men: a randomized, controlled trial.American journal of physiology. Endocrinology and metabolism · 2014Trial
- Trial
- Testosterone replacement therapy and cardiovascular risk.Nature reviews. Cardiology · 2019Review
- The Anti-Inflammatory Effects of Testosterone.Journal of the Endocrine Society · 2019Review
- Review
- Testosterone is protective against impaired glucose metabolism in male intrauterine growth-restricted offspring.PloS one · 2017Article
- Estrogens and Androgens in Skeletal Physiology and Pathophysiology.Physiological reviews · 2017Review
- Low Testosterone in Men with Cardiovascular Disease or Risk Factors: To Treat or Not To Treat?Current treatment options in cardiovascular medicine · 2016Review
- Comparative Safety of Testosterone Dosage Forms.JAMA internal medicine · 2015Article
- The role of testosterone therapy in cardiovascular mortality: culprit or innocent bystander?Current atherosclerosis reports · 2015Review
- The implications of low testosterone on mortality in men.Current sexual health reports · 2014Article
- Sex steroid actions in male bone.Endocrine reviews · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
Abstract
backgroundTestosterone in Older Men with Mobility Limitations Trial found an increased incidence of cardiovascular events in men randomized to testosterone, resulting in enrollment cessation by trial's Data and Safety Monitoring Board. We evaluated changes in gonadal hormones and markers of inflammation and coagulation to elucidate risk factors associated with cardiovascular events.
methodsMen aged 65 years or more, with mobility limitation, total testosterone 100-350 ng/dL, or free testosterone less than 50 pg/mL, were randomized to placebo or 10 g testosterone gel daily for 6 months. Changes in total and free testosterone, estradiol and estrone, C-reactive protein, interleukin 6, fibrinogen, plasminogen activator inhibitor-1, and pro-brain naturetic peptide were compared between groups and within the testosterone group between subjects who experienced cardiovascular events and those who did not.
resultsOf 209 men randomized (mean age 74 years), gonadal hormones and biomarkers were available in 179 men. Baseline body mass index, gonadal hormones, lipids, Framingham risk scores, and other biomarkers were similar in the two treatment groups. Within the testosterone group, the 6-month increase in free testosterone was significantly greater in men who experienced cardiovascular events than in those who did not [mean (95% confidence interval), 10.6 (4.6-16.7) vs 5.2 (3.0-7.5) ng/dL, p = .05]. In multivariable logistic regression analysis, the change in the serum levels of free testosterone was associated with cardiovascular events.
conclusionMobility-limited older men who experienced cardiovascular events had greater increases in serum free testosterone levels than those who did not.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.